BTCC / BTCC Square / Global Cryptocurrency /
Novo Nordisk Gains on Wegovy Heart Benefits While Eli Lilly Slips

Novo Nordisk Gains on Wegovy Heart Benefits While Eli Lilly Slips

Global Cryptocurrency
Release Time:
2025-09-02 10:48:02
0
BTCCSquare news:

Novo Nordisk shares ROSE 1.6% in pre-market trading after revealing its Wegovy weight-loss drug demonstrated a 57% reduction in cardiovascular risks—outpacing rival Eli Lilly's therapies. The Danish firm's real-world study of 21,000 patients showed superior efficacy to Lilly's clinical trial data, sending LLY shares down 1.7%.

The divergence underscores the competitive stakes in the GLP-1 drug market, where Novo's semaglutide appears to offer unique cardioprotective effects. Investors are repricing expectations as real-world evidence carries greater weight than controlled studies.

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users